BiliaryTractCancer near Newton, NJ

Care Philosophy: As a board-certified general surgeon and surgical oncologist, I firmly believe in providing the best care to all of my patients. I believe in spending time with patients and families to ensure that they understand all of the options available to them. When surgery is indicated and the best course of action, I provide patients with the best surgical and medical care to ensure they can return to their lives and families.

Biography: Dr. Khalid Dar, MD is a Hematology Specialist who practices in New York, NY. He is 75 years old and has been practicing for 51 years. Dr. Khalid Dar, MD is affiliated with Mount Sinai Morningside.

Biography: Dr. John Conti, MD is an Oncology Specialist who practices in Montclair, NJ. He is 65 years old and has been practicing for 39 years. Dr. John Conti, MD is affiliated with Clara Maass Medical Center.

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Care Philosophy: Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Fojo received his MD and PhD from the University of Miami and completed internal medicine training at Washington University School of Medicine / Barnes Hospital. He joined the National Cancer Institute in 1982 as a Clinical Associate in the Medicine Branch and after training with Drs. Ira Pastan and Michael Gottesman, became a Principal Investigator in the Medicine Branch of the National Cancer Institute. As a Principal Investigator he went on to establish a highly successful translational clinical program that began by exploring agents to reverse drug resistance, continued with work on the optimal use of Taxol®, and the development of novel microtubule-targeting agents and has focused on the development of therapies for endocrine and neuroendocrine cancers. Dr. Fojo has expertise in the management of patients with adrenocortical cancer, malignant pheochromocytoma and other neuroendocrine malignancies, and thyroid cancer. These cancers also comprise areas of very active basic science interest given their unique properties and the possibilities to target such cancers more precisely. The ultimate goal is to develop novel therapies for these often very refractory cancers so that there will be additional options available for treatment for patients with these cancers. Ongoing laboratory efforts are focused on developing such novel therapies to treat patients with adrenal cancer, pheochromocytoma and a spectrum of neuroendocrine tumors. In the laboratory Dr. Fojo has also worked to understand the molecular basis of drug resistance, and was involved in the original work relating to several ABC transporters. Additionally, his laboratory originally identified rearrangements involving the MDR-1 gene as a novel mechanism of drug resistance in several cancers, a molecular event recently demonstrated as very important in ovarian cancer. He has also been very involved in research on microtubule-targeting agents, helping to establish as a novel paradigm the interference with microtubule trafficking, rather than mitosis, for the mechanism of action for these important drugs. In addition to his clinical expertise Dr. Fojo has been very interested in the design, conduct and interpretation of oncology clinical trials and in collaboration with Wilfred Stein, PhD and Susan Bates, MD has helped to pioneer a novel method of analysis that dissects rates of tumor growth and regression as concurrent events. Related to this he has also written extensively about the cost of cancer therapeutics, the magnitude of the problem and how this might be addressed. Dr. Fojo served as Program Director for the Medical Oncology Fellowship Program at the National Cancer Institute, the largest fellowship program in the NIH and one of the largest medical oncology programs in the United States. Over the years Dr. Fojo has helped to train more than 350 medical oncologists.

Care Philosophy: As far back as I remember, I have been interested in improving the care of patients with cancer through research aimed at developing new and more effective therapies, and by providing compassionate care. I am fortunate to work at an institution that enables me to care for patients within an outstanding hospital and medical college, where I am surrounded by like-minded physicians and staff that are most concerned about the well-being of our patients and their family members. The close relationships I develop with my patients and the continued efforts by my colleagues and me to find a cure inspire me to come to work every day with new hope and determination.

Care Philosophy: Dr. Litvak believes in a shared decision-making approach and takes pride in educating and empowering her patients to jointly make decisions regarding management plans. Her goal is to optimize chance of cure and prolong survival while respecting and honoring one's individual needs and wishes.